Doxycycline capsules 100mg №10×1

Name Doxycycline caps. MNNDoxycycline FTG Antibiotic, tetracycline Ingredients One capsule contains: active substance: doxycycline (as doxycycline hyclate) – 100 mg; excipients – lactose monohydrate, potato starch, magnesium stearate. Capsule composition: gelatin, E 218 methyl parahydroxybenzoate, E 216 propyl parahydroxybenzoate, E 171 titanium dioxide, E 104 quinoline yellow, E 110 sunset yellow. Pharmacotherapeutic group Antibacterial agents for systemic use. Tetracyclines. ATX code: J01AA02. Indications for use Infectious diseases caused by pathogens sensitive to doxycycline. To prevent the development of resistance and maintain efficacy, the drug should only be used to treat infections caused by proven (or suspected) microorganisms susceptible to doxycycline. If there is information about the identified pathogen and its sensitivity to antibiotics, the doctor is guided by it to select the optimal antibiotic, and in the absence of such, the empirical choice of an antibacterial agent is based on local epidemiological data and sensitivity data. Doxycycline is indicated for the treatment of the following infections: – Rocky Mountain spotted fever, typhus and other types of typhus, Q-fever, Kew garden spotted fever, tick-borne fever caused by rickettsia; – respiratory tract infections caused by Mycoplasma pneumoniae; – venereal lymphogranuloma caused by Chlamydia trachomatis; – psittacosis (psittacosis) caused by Chlamydophila psittaci; – trachoma caused by Chlamydia trachomatis, despite the fact that the infectious agent is not always eliminated, as evidenced by immunofluorescence research; – conjunctivitis caused by Chlamydia trachomatis; – uncomplicated urethritis, cervical canal infections or rectal infections in adults caused by Chlamydia trachomatis; – non-gonococcal urethritis caused by Ureaplasma urealyticum; – relapsing fever caused by Borrelia recurrentis; Doxycycline is also indicated for the treatment of infections caused by the following gram-negative organisms: – chancre caused by Haemophilus ducreyi; – plague caused by Yersinia pestis; – tularemia caused by Francisella tularensis; – cholera caused by Vibrio cholerae; – campylobacteriosis caused by Campylobacter fetus; – brucellosis caused by bacteria of the Brucella variety (in combination with streptomycin); – bartonellosis caused by Bartonella bacilliformis; – inguinal granuloma caused by the bacteria Klebsiella granulomatis. Since many strains of microorganisms are known to be resistant to doxycycline, culture and antibiotic susceptibility testing is recommended. Doxycycline is used to treat infections caused by the following gram-negative microorganisms, if bacteriological examination confirms their sensitivity to the drug: Escherichia coli; Enterobacter aerogenes; Shigella species; Acinetobacter species; respiratory tract infections caused by Haemophilus influenzae; respiratory and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for the treatment of infections caused by the following Gram-positive organisms, if bacteriological examination shows sensitivity to the drug: – anthrax due to Bacillus anthracis, including pulmonary anthrax (after contact), to reduce the incidence or progression of the disease after airborne exposure to Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: – uncomplicated gonorrhea caused by Neisseria gonorrhoeae; – syphilis caused by Treponema pallidum; – yaws caused by Treponema pallidum subspecies pertenue; – listeriosis caused by Listeria monocytogenes; – Vincent’s infection caused by Fusobacterium fusiforme; – actinomycosis caused by Actinomyces israelii; – infections caused by Clostridium spesies. Doxycycline may be useful as an additional drug in the treatment of acute intestinal amoebiasis, severe acne. Doxycycline is indicated for the prevention of Plasmodium falciparum malaria in the short term (<4 months) in areas where strains resistant to chloroquine and/or pyrimethamine sulfadoxine are found. Contraindications - hypersensitivity to doxycycline and other tetracyclines; - hypersensitivity to the auxiliary components of the drug; - children's age up to 12 years; - pregnancy and breastfeeding; - leukopenia; -porphyria; - severe violations of the liver and kidneys. Dosage and administration Before using the drug, you should always consult with your doctor. The drug is taken orally during or after a meal with a glass of water. Capsules are taken in a sitting or standing position and well before bedtime to reduce the risk of irritation and ulceration of the esophagus. If signs of stomach irritation are observed, it is recommended that doxycycline be taken with food or milk. The usual dose for the treatment of acute infections in adults and children over 12 years of age weighing more than 45 kg is 200 mg (2 capsules) in 1 or 2 doses on the first day, 100 mg (1 capsule) 1 time per day from the second day. The maximum daily dose for severe infections is 200 mg / day in 1-2 doses (especially for chronic urinary tract infections). The duration of treatment depends on the type of infection and is usually 5-10 days. With Lyme disease, the course of treatment is 3-4 weeks, with brucellosis - 1.5-6 months. Therapy should continue for at least 24-48 hours after the symptoms of the disease have disappeared. In the case of streptococcal infection, the duration of therapy should be at least 10 days to prevent rheumatism or glomerulonephritis. Uncomplicated gonococcal infection in adults (excluding anorectal infection in men): 100 mg 2 times a day for 7 days. Alternatively: initial dose of 300 mg followed by a second dose of 300 mg an hour later. Uncomplicated urethritis, endocervicitis or infection of the rectum in adults caused by C. trachomatis: 100 mg 2 times a day for 7 days. Non-gonococcal urethritis caused by C. trachomatis or U. urealyticum: 100 mg 2 times a day for 7 days. Early syphilis: 100 mg 2 times a day for 2 weeks (for non-pregnant patients allergic to penicillin). Syphilis lasting more than one year: 100 mg 2 times a day for 4 weeks (for non-pregnant patients allergic to penicillin). Acute epididymo-orchitis caused by N. gonorrhoeae or C. trachomatis: 100 mg 2 times a day for at least 10 days. In the treatment of acne - 50 mg / day for 6-12 weeks. Treatment of malaria due to chloroquine-resistant P. falciparum: 200 mg/day for at least 7 days. Given the potential severity of the infection, a fast-acting schizonticidal drug, such as quinine, should be used concomitantly with doxycycline, the recommended dosages of which vary by region. Malaria prophylaxis: 100 mg/day in adults; in children over the age of 12 years, the drug is prescribed at a dose of 2 mg / kg 1 time per day; the dose can reach that for adults. Prophylaxis can be given 1-2 days before traveling to an area where malaria occurs. It should be continued throughout the trip and for 4 weeks after returning. Prevention of Japanese river fever: 200 mg once orally. Prevention of traveler's diarrhea in adults: 200 mg on the first day of travel (once or 100 mg every 12 hours), then 100 mg/day throughout the stay in the region. There is no information on the prophylactic use of the drug for more than 21 days. Prevention of leptospirosis: 200 mg orally once a week throughout the stay in the region and 200 mg at the end of the trip. There is no information on the prophylactic use of the drug for more than 21 days. Pulmonary anthrax (after exposure): adults 100 mg orally 2 times a day for 60 days. Children weighing less than 45 kg, 2.2 mg / kg orally 2 times a day for 60 days. In children weighing more than 45 kg, doxycycline is used at the usual adult dose. In tick-borne and lousy relapsing fever, doxycycline has been successfully used once at a dose of 100 mg or 200 mg, depending on the severity of the infection. In order to reduce the risk of persistence or recurrence of tick-borne relapsing fever, it is recommended to use doxycycline 100 mg every 12 hours for 7 days. Elderly patients: dose adjustment is not required. Hepatic impairment: Doxycycline should be used with caution in patients with hepatic impairment or in patients receiving potentially hepatotoxic medicinal products. Renal impairment: Studies have shown that the use of doxycycline at the usual recommended doses does not lead to excessive accumulation of the antibiotic in patients with impaired renal function. In the presence of renal insufficiency, dose adjustment is not required. If the drug was not taken at the exactly appointed time, it is necessary to take it as soon as possible (if there is still a lot of time before the next drug intake) or continue taking the drug regularly. Do not take a double dose to make up for the missed one. Side effects In patients receiving doxycycline, the following adverse reactions were observed: - from the nervous system: headache; benign intracranial hypertension (symptoms include blurred vision, scotoma, and diplopia; cases of permanent vision loss have been reported); - on the part of the organ of hearing: noise (ringing) in the ears; - from the side of the cardiovascular system: tachycardia, edema, pericarditis, hypotension; - from the digestive system: nausea, vomiting, constipation and diarrhea, abdominal pain, glossitis, dysphagia, esophagitis (including erosive), gastritis, ulceration of the stomach and duodenum, dyspepsia, enterocolitis (due to the proliferation of resistant strains of staphylococci ), pseudomembranous colitis, pancreatitis, esophageal ulcers; - on the part of metabolism and nutrition: anorexia; - from the immune system: allergic reactions, including anaphylactic shock, anaphylaxis, anaphylactoid reactions, angioedema, shortness of breath, exacerbation of systemic lupus erythematosus, serum sickness, peripheral edema, urticaria. You should immediately consult a doctor if you develop any of the following adverse events: Jarisch-Herxheimer reaction, manifested by fever, chills, headache and muscle pain, skin rash. As a rule, it disappears spontaneously. It develops shortly after the start of doxycycline in the treatment of infections caused by spirochetes, such as Lyme disease. - on the skin side: maculopapular rash, pruritus, skin hyperemia, photoonycholysis, exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, DRESS syndrome, toxic epidermal necrolysis, photosensitivity; - on the part of the hematopoietic organs: hemolytic anemia, thrombocytopenia, neuropenia, eosinophilia, porphyria; - from the side of the kidneys and urinary tract: an increase in the concentration of urea in the blood serum; - from the musculoskeletal system: atralgia, myalgia; - from the hepatobiliary system: jaundice, hepatitis, hepatotoxicity (transient increase in the functional state of the liver), liver failure (isolated cases); - others: superinfection, persistent discoloration of tooth enamel, inflammation in the anogenital zone, candidiasis (vaginitis, glossitis, stomatitis, proctitis), dysbacteriosis, hot flashes, microscopic discoloration of the thyroid tissue without impaired thyroid function. Reporting adverse reactions If you experience any adverse reactions, it is recommended that you consult your doctor. This recommendation applies to any possible adverse reactions, including those not listed in the package insert for the use of the medicinal product. You can also report adverse drug reactions, including reports of drug inefficiency, to: Republican Unitary Enterprise "Center for Expertise and Testing in Healthcare", per. Comradely, 2a, 220037, Republic of Belarus, e-mail: [email protected]. By reporting adverse reactions, you help to get more information about the safety of the drug. Precautions The composition of the medicinal product includes dyes quinoline yellow E 104 and sunset yellow E 110, parabens (methyl parahydroxybenzoate E 218 and propyl parahydroxybenzoate E 216), which can cause allergic reactions (including delayed ones). The medicinal product contains lactose, therefore patients with hereditary galactose intolerance, glucose-galactose malabsorption syndrome and the Lapp lactase deficiency should not use this medicinal product. Use in patients with impaired liver function. Doxycycline should be used with caution in patients with hepatic impairment or in those receiving potentially hepatotoxic medicinal products. Hepatic impairment associated with oral or parenteral tetracyclines, including doxycycline, has been reported very rarely. Use in patients with impaired renal function. Excretion of doxycycline through the kidneys is approximately 40% in 72 hours in individuals with normal renal function. This range may decrease to 1-5% in 72 hours in individuals with severe renal insufficiency (creatinine clearance (CC) below 10 ml / min). Studies have not shown a significant difference in the half-life of doxycycline from serum in individuals with normal and impaired renal function. Hemodialysis does not affect the half-life of the drug from the blood serum. The antianabolic effect of tetracyclines can lead to an increase in the level of urea in the blood. The antianabolic effect was not manifested when using doxycycline in patients with impaired renal function. It is necessary to monitor renal function during long-term therapy with doxycycline. risk of superinfection. As with other antibacterial agents, the use of doxycycline may lead to overgrowth of non-susceptible organisms, including fungi. With the development of superinfection, the use of doxycycline should be discontinued and appropriate therapy initiated. Antibiotic-associated colitis. Colitis has been reported with almost all antibacterial agents, including doxycycline. The severity of this complication ranged from mild to life threatening. This diagnosis should be considered in patients presenting with diarrhea due to the use of antibacterial agents. There are reports of cases of Clostridium difficile associated diarrhea (CDAD), the severity of which can vary from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal intestinal flora, leading to the growth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. The hypertoxin produced by C. difficile strains results in increased morbidity and mortality because these infections may be resistant to antimicrobial therapy. Esophagitis. Cases of esophagitis and esophageal ulcers have been reported in patients treated with encapsulated or tablet forms of the tetracycline class of drugs, including doxycycline. Most of these patients took the drug just before bedtime or with insufficient fluids. Porfiry. Rare cases of porphyria have been observed in patients treated with tetracyclines. Intracranial hypertension (VH, pseudotumor of the brain). Cases of CH have been reported in patients treated with tetracyclines, including doxycycline. Clinical manifestations of VH include headache, blurred vision, diplopia, vision loss, and papilledema (when examining the fundus). Women of childbearing age who are overweight or have a history of CH are at risk for tetracycline-associated CH. The simultaneous use of isotretinoin and doxycycline should be avoided, since isotretinoin is known to cause brain pseudotumor. Although VH usually resolves after treatment is stopped, there is a risk of permanent vision loss. If visual disturbances occur during treatment, consultation with an ophthalmologist is recommended. Since intracranial pressure may remain elevated for several weeks, after discontinuation of treatment with the drug, patients should be observed for several more weeks until the condition stabilizes. Systemic lupus erythematosus. Tetracyclines can exacerbate systemic lupus erythematosus. Myasthenia gravis. Tetracycline drugs can cause mild neuromuscular blockade, so doxycycline should be used with caution in patients with myasthenia gravis. Venereal diseases. Appropriate diagnostic procedures, including dark field microscopy and other tests, should be used in the treatment of sexually transmitted diseases with suspected concomitant syphilis. In such cases, monthly serological tests should be performed for (at least) 4 months. Methoxyflurane. Caution should be exercised when co-administering doxycycline and methoxyflurane. The simultaneous use of methoxyflurane with tetracyclines leads to fatal nephrotoxicity. Doxycycline significantly, but not completely, suppresses asexual forms of Plasmodium strains in the blood. Individuals who have completed doxycycline prophylaxis may still carry mosquito-borne infection outside the endemic area. Caution when using. In connection with the possible development of photosensitivity, it is necessary to limit insolation during treatment and for 4-5 days after it. To prevent the development of erosive and ulcerative lesions of the esophagus, it is recommended to drink doxycycline with plenty of water (200-300 ml). If it is necessary to use doxycycline for a long time, it is necessary to periodically (at least 1 time in 5-7 days) monitor the indicators of peripheral blood, liver and kidney functions. Impact on laboratory parameters. During treatment with doxycycline, false positive results may occur when determining the level of catecholamines in the urine by the fluorescent method. In the study of biopsy specimens of the thyroid gland in persons who have received doxycycline for a long time, their brown staining is possible, which does not indicate pathology. Use in pediatrics. Use in children under 12 years of age is contraindicated, since doxycycline can lead to a violation of the formation of the skeleton, teeth, cause hypoplasia and irreversible staining of tooth enamel in a yellow-gray-brown color. In children over 12 years of age with a body weight of up to 45 kg, the drug must be used in a different dosage form. Pregnancy and lactation Pregnancy. In animal experiments, doxycycline has been shown to delay fetal skeletal development. Its use during pregnancy is contraindicated. lactation period. In connection with the entry of doxycycline into the mother's milk, breastfeeding is stopped for the duration of treatment. Influence on the ability to drive vehicles or other mechanisms There are no data on the effect of doxycycline on the ability to drive vehicles or other mechanisms. Interactions with other drugs If you are taking any other drugs, be sure to inform your doctor, and if you are self-treating, consult your doctor about the possibility of using the drug. Absorption of doxycycline may be impaired when taken concomitantly with antacids containing aluminum, calcium, magnesium, and other drugs that contain these cations, as well as zinc, iron or bismuth salts. These medicines should be taken as far apart as possible. Doxycycline enhances the effect of indirect anticoagulants by suppressing the intestinal flora and reducing the synthesis of vitamin K. Tetracyclines reduce plasma prothrombin activity, it may be necessary to reduce the dose of co-administered anticoagulants. Doxycycline reduces the effectiveness of estrogen-containing oral contraceptives and increases the incidence of breakthrough bleeding. Drugs that induce microsomal liver enzymes (barbiturates, phenytoin, carbamazepine, rifampicin) increase the metabolism of doxycycline and reduce its concentration in the blood. An increase in the daily dose of doxycycline may be required. Penicillins and doxycycline mutually weaken each other's antimicrobial action. Therefore, the combined use of these antibiotics should be avoided. Kolestiramin and colestipol reduce the absorption of doxycycline in the intestine. The retinoid isotretinoin enhances the neurotoxic effect of doxycycline and increases the likelihood of developing intracranial hypertension. Doxycycline may increase the plasma concentration of cyclosporine. The combined use of these drugs should be carried out only under medical supervision. The combined use of tetracyclines and methoxyflurane (an agent for inhalation anesthesia) can lead to the development of severe renal failure (including death). Milk reduces the degree and rate of absorption of doxycycline. Regular alcohol consumption shortens the half-life of doxycycline and accelerates its elimination. Overdose In case of overdose, stop taking the drug and start symptomatic treatment. Dialysis does not affect the serum half-life and is ineffective in case of overdose. Upakovka10 capsules in a blister pack of PVC film and aluminum foil. 1 or 2 blister packs, together with the leaflet, are placed in a pack of cardboard. Storage conditions In a place protected from light and moisture, at a temperature not exceeding 25 ° C. Keep out of the reach of children. Terms of dispensing from pharmacies By prescription. Shelf life 3 years. Do not use after the expiration date. Buy Doxycycline capsules 100mg No. 10x1 Price for Doxycycline capsules 100mg No. 10x1